Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289640 · ClinicalTrials.gov registry record · Phase 2
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT00289640 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 210 participants.
The verdict
NCT00289640, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory, or -intolerant, Stage III (unresectable) or Stage IV melanoma receiving ipilimumab doses of 0.3, 3, and 10 mg/kg. The safety of this product will also be evaluated.
Interventions
- DRUG Ipilimumab
- DRUG ipilimumab (MDX-010, BMS-734016)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00289640
The ClinicalTrials.gov registry entry for NCT00289640 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT00289640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00289640 about?
NCT00289640 is a clinical study titled "Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma". The purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory, or -intolerant, Stage III (unresectable) or Stage IV melanoma receiving ipilimumab doses of 0.3, 3, and 10 mg/kg. The...
What is the current status of trial NCT00289640?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2006-04. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00289640?
The interventions under investigation include: Ipilimumab (DRUG), ipilimumab (MDX-010, BMS-734016) (DRUG).
Who is sponsoring clinical trial NCT00289640?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.